News Sentiment

BDTX sentiment intelligence

Black Diamond Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed

Weighted score 54 Balanced news tone 59 relevant articles

Exchange NASDAQ United States

Sector Healthcare Market context

Industry Biotechnology Read-through group

Latest close 1.91 Week of 10 Jul 2026

Weighted tone 54/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

79/100 classification confidence.

Company focus 50

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

-5.0% over one week, +9.1% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

Black Diamond Therapeutics (BDTX) 24th Annual Needham Virtual Healthcare Conference summary

Market Reaction

Price moving ahead of tone

62/100 confidence

Primary event Market update 79/100 classification

One-week reaction -5.0% Price reacting lower

Trend fit Trend inactive 9.1% over four weeks

Fair value -40.7% Below fair value

Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance

Positive 14

Neutral 42

Negative 3

Relevance

Why the article matched

Direct first

Direct company coverage 50

Industry context 9

Sector context 0

Sources

Coverage mix

Publishers

Market source 13

Stock Titan 11

TradingView 7

www.marketscreener.com 3

TradingKey 3

GlobeNewswire 3

simplywall.st 3

Quartr 2

Event Lens

What the news is about

Classified themes

Market update 31

Earnings 20

Regulatory and legal 3

Deals and strategy 1

Balance sheet 1

Capital return 1

Guidance 1

Analyst action 1

Sentiment Trail

Score over time

50 baseline

Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-59 of 59

TradingKey Direct company coverage

Black Diamond Therapeutics Inc (BDTX) Valuation: PE, PB & Fair Value Analysis

This article analyzes the valuation of Black Diamond Therapeutics Inc (BDTX), noting its current valuation score of 6.68, which places it in the lower rankings within the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -2.19, indicating a signi

Tone: Neutral 50/100
Event: Market update
Published: 16 Jun 2026 15:39
Source: TradingKey

MSN Direct company coverage

Black Diamond Therapeutics touts Silevertinib lung cancer data, eyes FDA path

The article discusses Black Diamond Therapeutics' promising lung cancer data for its drug Silevertinib. The company is evaluating its FDA approval pathway based on these results.

Tone: Positive 73/100
Event: Earnings
Published: 13 Jun 2026 01:40
Source: MSN

Market source Direct company coverage

Black Diamond Stock Outlook After Q1 Beat and Cash Runway

Tone: Positive 66/100
Event: Guidance
Published: 27 May 2026 07:00
Source: Market source

GlobeNewswire Direct company coverage

Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference

Tone: Neutral 50/100
Event: Market update
Published: 22 May 2026 12:00
Source: GlobeNewswire

MarketBeat Direct company coverage

Black Diamond Therapeutics Lung Cancer Drug Shows 15.2-Month PFS in Phase 2 Study

Tone: Neutral 50/100
Event: Market update
Published: 21 May 2026 23:09
Source: MarketBeat

GlobeNewswire Direct company coverage

Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations

Tone: Positive 58/100
Event: Earnings
Published: 21 May 2026 21:13
Source: GlobeNewswire

Quiver Quantitative Direct company coverage

Black Diamond Therapeutics Announces Encouraging Phase 2 Trial Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations

Tone: Neutral 50/100
Event: Earnings
Published: 21 May 2026 07:00
Source: Quiver Quantitative

GlobeNewswire Direct company coverage

Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC

Tone: Neutral 50/100
Event: Earnings
Published: 19 May 2026 12:00
Source: GlobeNewswire

Stock Titan Direct company coverage

Lung cancer drug trial results to be detailed in Black Diamond webcast

Tone: Neutral 50/100
Event: Earnings
Published: 19 May 2026 07:00
Source: Stock Titan

simplywall.st Industry context

There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings

Tone: Negative 34/100
Event: Earnings
Published: 15 May 2026 07:00
Source: simplywall.st

Market source Industry context

Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings

Tone: Neutral 50/100
Event: Earnings
Published: 14 May 2026 07:00
Source: Market source

Market source Direct company coverage

Black Diamond Therapeutics (NASDAQ:BDTX) Is In A Good Position To Deliver On Growth Plans

Tone: Positive 66/100
Event: Market update
Published: 11 May 2026 07:00
Source: Market source

simplywall.st Industry context

Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results

Tone: Positive 66/100
Event: Earnings
Published: 11 May 2026 07:00
Source: simplywall.st

Market source Industry context

Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00

Tone: Neutral 50/100
Event: Earnings
Published: 11 May 2026 07:00
Source: Market source

Market source Industry context

Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks

Tone: Neutral 50/100
Event: Earnings
Published: 25 Apr 2026 07:00
Source: Market source

Quiver Quantitative Direct company coverage

Black Diamond Therapeutics Announces Multiple Presentations on Silevertinib at 2026 ASCO Annual Meeting

Tone: Neutral 50/100
Event: Market update
Published: 21 Apr 2026 07:00
Source: Quiver Quantitative

Stock Titan Direct company coverage

Lung cancer drug data from Black Diamond gets ASCO oral slot

Tone: Neutral 50/100
Event: Market update
Published: 21 Apr 2026 07:00
Source: Stock Titan

Market source Industry context

Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)

Tone: Neutral 50/100
Event: Earnings
Published: 21 Apr 2026 07:00
Source: Market source

Market source Direct company coverage

Why Is Black Diamond (BDTX) Up 19.3% Since Last Earnings Report?

Tone: Neutral 50/100
Event: Earnings
Published: 15 Apr 2026 07:00
Source: Market source

TradingView Industry context

A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack

Tone: Neutral 50/100
Event: Earnings
Published: 29 Mar 2026 07:00
Source: TradingView

Market source Direct company coverage

Wedbush Bullish on Black Diamond Therapeutics (BDTX) Following Progress in Silevertinib Program

Tone: Positive 66/100
Event: Market update
Published: 25 Mar 2026 07:00
Source: Market source

simplywall.st Direct company coverage

Black Diamond Therapeutics (BDTX) Profit Swing To US$0.81 EPS Challenges Bearish Earnings Narratives

Tone: Neutral 50/100
Event: Earnings
Published: 18 Mar 2026 07:00
Source: simplywall.st

Market source Direct company coverage

Black Diamond Therapeutics, Inc. (BDTX) Price Target Trimmed as Piper Updates Biotech Models and 2026 Catalyst Tracker

Tone: Neutral 50/100
Event: Analyst action
Published: 02 Feb 2026 08:00
Source: Market source

Market source Direct company coverage

What Makes Black Diamond (BDTX) a New Strong Buy Stock

Tone: Positive 82/100
Event: Market update
Published: 09 Jan 2026 08:00
Source: Market source

Market source Direct company coverage

Black Diamond Therapeutics And 2 Promising Penny Stocks For Savvy Investors

Tone: Neutral 50/100
Event: Market update
Published: 18 Aug 2025 07:00
Source: Market source

MarketBeat Direct company coverage

Black Diamond Therapeutics (BDTX) FDA Approvals, PDUFA Dates & Drug Alerts 2026

Tone: Neutral 50/100
Event: Market update
Published: 09 Jul 2025 17:05
Source: MarketBeat

Stock Titan Direct company coverage

Black Diamond Therapeutics (BDTX) Stock Price, News & Analysis

Tone: Neutral 50/100
Event: Market update
Published: 25 Apr 2025 01:15
Source: Stock Titan

timothysykes.com Direct company coverage

Black Diamond Therapeutics: Is Now the Time to Buy or Run Away?

Tone: Positive 66/100
Event: Market update
Published: 23 Sep 2024 07:00
Source: timothysykes.com

Zacks Investment Research Direct company coverage

Black Diamond Therapeutics (BDTX)

Tone: Neutral 50/100
Event: Market update
Published: 05 Feb 2020 20:22
Source: Zacks Investment Research